Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
South Korea · Delayed Price · Currency is KRW 4,030.00
+85.00 (2.15%)
At close: Aug 24, 2026
Jin Yang Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 124,611 | 120,686 | 113,332 | 93,708 | 76,264 | 62,839 |
Other Revenue | -0 | - | -0 | - | -0 | - |
| 124,611 | 120,686 | 113,332 | 93,708 | 76,264 | 62,839 | |
Revenue Growth | 4.12% | 6.49% | 20.94% | 22.87% | 21.36% | 26.88% |
Cost of Revenue | 42,353 | 42,535 | 43,448 | 36,652 | 30,613 | 28,856 |
Gross Profit | 82,257 | 78,151 | 69,884 | 57,056 | 45,651 | 33,984 |
Selling, General & Admin | 77,320 | 72,891 | 59,052 | 46,381 | 33,981 | 27,965 |
Other Operating Expenses | 682.19 | 657.35 | 205.11 | 170.02 | 139.73 | 146.93 |
Operating Expenses | 78,467 | 75,625 | 58,175 | 48,374 | 34,513 | 27,020 |
Operating Income | 3,790 | 2,526 | 11,708 | 8,682 | 11,138 | 6,964 |
Interest Expense | -2,247 | -2,292 | -1,855 | -1,374 | -1,285 | -208.28 |
Interest & Investment Income | 134.31 | 41.68 | 481.5 | 1,472 | 356.59 | 16.99 |
Currency Exchange Gain (Loss) | 8.68 | -1.41 | -2.38 | -1.69 | 3.53 | -0.2 |
Other Non Operating Income (Expenses) | -16.37 | -1,093 | 2,439 | 937.36 | 839.11 | 3,913 |
EBT Excluding Unusual Items | 1,670 | -818.66 | 12,771 | 9,716 | 11,053 | 10,685 |
Gain (Loss) on Sale of Investments | 28,407 | 28,888 | 24,298 | 2,253 | 3,132 | 1,438 |
Gain (Loss) on Sale of Assets | 29.93 | 31.33 | -77.14 | 0.86 | 24.9 | 9.53 |
Asset Writedown | -991.9 | - | - | - | 325.53 | - |
Other Unusual Items | - | - | 62.21 | 210.2 | - | - |
Pretax Income | 29,115 | 28,101 | 37,054 | 12,180 | 14,535 | 12,132 |
Income Tax Expense | 6,310 | 5,814 | 7,360 | -160 | 2,227 | 2,594 |
Net Income | 22,804 | 22,287 | 29,694 | 12,340 | 12,308 | 9,538 |
Net Income to Common | 22,804 | 22,287 | 29,694 | 12,340 | 12,308 | 9,538 |
Net Income Growth | -20.66% | -24.95% | 140.63% | 0.26% | 29.05% | 82.41% |
Shares Outstanding (Basic) | - | 12 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | - | 12 | 12 | 12 | 13 | 11 |
Shares Change | - | 1.00% | -1.17% | -7.18% | 17.77% | 2.12% |
EPS (Basic) | - | 1828.24 | 2692.30 | 1145.09 | 1114.86 | 853.30 |
EPS (Diluted) | - | 1789.41 | 2408.01 | 988.98 | 915.61 | 835.60 |
EPS Growth | - | -25.69% | 143.48% | 8.01% | 9.57% | 78.63% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 2,838 | -2,801 | -77,268 | 7,851 | 4,230 | -545.86 |
Free Cash Flow Per Share | - | -224.88 | -6265.96 | 629.22 | 314.65 | -47.82 |
Gross Margin | 66.01% | 64.76% | 61.66% | 60.89% | 59.86% | 54.08% |
Operating Margin | 3.04% | 2.09% | 10.33% | 9.26% | 14.61% | 11.08% |
Profit Margin | 18.30% | 18.47% | 26.20% | 13.17% | 16.14% | 15.18% |
Free Cash Flow Margin | 2.28% | -2.32% | -68.18% | 8.38% | 5.55% | -0.87% |
EBITDA | 6,348 | 4,935 | 13,733 | 11,337 | 13,429 | 9,117 |
EBITDA Margin | 5.09% | 4.09% | 12.12% | 12.10% | 17.61% | 14.51% |
D&A For EBITDA | 2,557 | 2,409 | 2,024 | 2,655 | 2,291 | 2,154 |
EBIT | 3,790 | 2,526 | 11,708 | 8,682 | 11,138 | 6,964 |
EBIT Margin | 3.04% | 2.09% | 10.33% | 9.26% | 14.61% | 11.08% |
Effective Tax Rate | 21.68% | 20.69% | 19.86% | - | 15.32% | 21.38% |
Advertising Expenses | - | 3,268 | 3,748 | 3,869 | 2,541 | 2,125 |